Online citations, reference lists, and bibliographies.
← Back to Search

Isoniazid Pharmacokinetics-Pharmacodynamics In An Aerosol Infection Model Of Tuberculosis

R. Jayaram, R. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, Sowmya Bharath, E. Kantharaj, V. Balasubramanian
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Limited data exist on the pharmacokinetic-pharmacodynamic (PK-PD) parameters of the bactericidal activities of the available antimycobacterial drugs. We report on the PK-PD relationships for isoniazid. Isoniazid exhibited concentration (C)-dependent killing of Mycobacterium tuberculosis H37Rv in vitro, with a maximum reduction of 4 log10 CFU/ml. In these studies, 50% of the maximum effect was achieved at a C/MIC ratio of 0.5, and the maximum effect did not increase with exposure times of up to 21 days. Conversely, isoniazid produced less than a 0.5-log10 CFU/ml reduction in two different intracellular infection models (J774A.1 murine macrophages and whole human blood). In a murine model of aerosol infection, isoniazid therapy for 6 days produced a reduction of 1.4 log10 CFU/lung. Dose fractionation studies demonstrated that the 24-h area under the concentration-time curve/MIC (r2 = 0.83) correlated best with the bactericidal efficacy, followed by the maximum concentration of drug in serum/MIC (r2 = 0.73).
This paper references
10.1128/AAC.43.5.1189
Activities of Several Novel Oxazolidinones againstMycobacterium tuberculosis in a Murine Model
M. Cynamon (1999)
10.1128/AAC.36.3.548
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
J. Grosset (1992)
10.1128/AAC.40.12.2809
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.
B. P. Kelly (1996)
10.1007/BF01588176
Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: Ultrastructure and drug-susceptibility studies
Nalin Rastogi (2005)
10.1378/CHEST.76.6_SUPPLEMENT.771
Basic mechanisms of chemotherapy.
D. Mitchison (1979)
10.1164/AJRCCM.156.3.9609132
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.
P. Donald (1997)
10.1164/ARRD.1965.91.3.440
FURTHER STUDIES ON THE TIME/CONCENTRATION RELATIONSHIPS OF ISONIAZID AND TUBERCLE BACILLI IN VITRO.
Armstrong Ar (1965)
10.1086/346053
Whole blood bactericidal activity during treatment of pulmonary tuberculosis.
R. Wallis (2003)
10.1128/AAC.39.3.750
Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis.
P. Skinner (1995)
10.1016/0041-3879(91)90013-I
A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment.
D. Smith (1991)
10.1016/0378-4347(96)82886-6
High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.
H. Seifart (1995)
10.1128/AAC.40.10.2296
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
D. Herbert (1996)
10.1164/arrd.1965.91.3.440
FURTHER STUDIES ON THE TIME/CONCENTRATION RELATIONSHIPS OF ISONIAZID AND TUBERCLE BACILLI IN VITRO.
A. Armstrong (1965)
10.1086/321854
Does the dose matter?
W. Craig (2001)
Role of individual drugs in the chemotherapy of tuberculosis.
D. Mitchison (2000)
10.1159/000220725
The combination of rifampicin and other antituberculous agents in chronic murine tuberculosis.
F. Kradolfer (1971)
10.1086/319679
A whole blood bactericidal assay for tuberculosis.
R. Wallis (2001)
10.1128/AAC.47.7.2118-2124.2003
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
R. Jayaram (2003)
10.1128/AAC.47.7.2283-2292.2003
Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 Macrophages
C. Seral (2003)
parison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis
D. W. Smith (1995)



This paper is referenced by
10.1093/cid/cis353
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
J. Pasipanodya (2012)
10.1021/jm201716n
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.
Sumandeep K Gill (2012)
10.1128/AAC.01355-09
Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium
Devyani S. Deshpande (2010)
The impact of oxytetracycline dosing on bacterial populations and transfer of resistance elements in vitro and in vivo
Brian V. Lubbers (2009)
10.1111/bph.15247
Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
Rob C van Wijk (2020)
10.1016/j.coph.2011.07.001
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
J. Pasipanodya (2011)
10.1086/605605
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Zahoor Ahmad (2009)
10.22270/jddt.v9i3.2805
Therapeutic Management of Pulmonary Tuberculosis by Mannosylated Chitosan Ascorbate Microspheres: Preparation and Characterization
Archana Bagre (2019)
10.1002/cpt.180
Optimizing the clinical pharmacology of tuberculosis medications
E. Egelund (2015)
10.1016/j.tube.2017.11.004
The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.
C. Sekaggya-Wiltshire (2018)
10.1007/978-981-15-3895-7_9
Pharmacogenomics in Therapeutic Drug Monitoring
Bing Chen (2020)
10.1128/AAC.00849-10
PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
Zahoor Ahmad (2010)
10.1128/AAC.01474-09
New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
T. Gumbo (2010)
10.4155/fmc.10.224
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
P. Vaddady (2010)
10.1093/cid/cis366
Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance.
E. Egelund (2012)
10.1159/000153314
Evaluation of Killing Kinetics of Anti-Tuberculosis Drugs on Mycobacterium tuberculosis Using a Bacteriophage-Based Assay
Nimi Marcel (2008)
10.1021/bc500476x
Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
K. Horváti (2014)
10.1016/j.cca.2009.03.045
Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects.
B. Chen (2009)
10.5772/54278
Research and Development of New Drugs Against Tuberculosis
Juan D. Guzman (2013)
therapeutic drug monitoring of first-line anti-tuberculosis drugs
Sturkenboom (2016)
10.1093/jac/dku478
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.
Hiwot Hiruy (2015)
10.1371/journal.pmed.1002773
Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization
Natasha Strydom (2019)
10.1371/journal.pone.0196322
Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
E. Pienaar (2018)
10.1371/journal.pcbi.1008107
Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis
John Fors (2020)
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
G. R. Daviesa (2008)
10.3384/DISS.DIVA-156494
Towards individualised treatment of tuberculosis
K. Niward (2019)
Pharmacokinetic/pharmacodynamic relationship and simulation analysis for the evaluation of isoniazid hepatotoxicity risk development in patients with tuberculosis
P. G. Cojutti (2015)
10.4314/TJPR.V15I11.24
Simultaneous determination of isoniazid and pyrazinamide in plasma by high performance liquid chromatography
Abdallah Abdallah Mahjoub (2016)
10.1515/DMDI.2011.016
Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects
C. Bing (2011)
10.1093/jac/dku210
Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
J. Prahl (2014)
10.21007/ETD.CGHS.2009.0039
A PHARMACOKINETICS AND PHARMACODYNAMICS (PK/PD) GUIDED APPROACH TO LEAD OPTIMIZATION OF NITROFURANYLAMIDE ANTI-TUBERCULOSIS AGENTS
N. Budha (2009)
10.1093/jac/dkv247
Quantifying the impact of drug combination regimens on TB treatment efficacy and multidrug resistance probability.
Yi-Jun Lin (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar